|
|
News Breaks | | | | March 19, 2013 | | 10:01 EDT |  | NYMX | Nymox says IDMC for Phase 2 NX-1207 study reports third positive analysis
Nymox Pharmaceutical announced that the Independent Data Monitoring Committee for the company's Phase 2 study of NX-1207 for low risk localized prostate cancer has reported a third positive analysis of safety data from the clinical trial. The Independent Data Monitoring Committee assessed all patients to date who had received NX-1207 for treatment of their localized prostate cancer. The Committee has the authority to recommend changes to the study or to halt the study in the event of unacceptable drug toxicity. The Committee's interim safety analysis found no evidence of such toxicity and accordingly the study is continuing. NX-1207 is also in late stage Phase 3 development in the U.S. for the treatment of benign prostatic hyperplasia, a common condition of older men associated with growth in prostate size as men age. Phase 3 trial activities of NX-1207 for BPH have recently begun in Europe sponsored by Recordati S.p.A., the company's European licensing partner for the BPH indication. | |
|
News For NYMX From The Last 14 Days Check below for free stories on NYMX the last two weeks. |
|
|
| May 15, 2013 | | 09:46 EDT |  | NYMX | Nymox reports Q1 EPS (3c), consensus (5c)
 Subscribe for More Information | |
|
|
|
|
|
|
